Medical research

Improving treatment for hairy cell leukemia

Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.

Oncology & Cancer

Study links genetic mutation and melanoma progression

Dartmouth researchers have found that the genetic mutation BRAFV600E, frequently found in metastatic melanoma, not only secretes a protein that promotes the growth of melanoma tumor cells, but can also modify the network ...

Oncology & Cancer

Dabrafenib: Also no added benefit over vemurafenib

Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal ...

Medications

Vemurafenib: Result unchanged despite new data

Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment ...